HC Wainwright & Co. Reiterates Buy on PDS Biotechnology, Maintains $21 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on PDS Biotechnology, maintaining a price target of $21. Analyst Joseph Pantginis continues to support the stock's potential.
September 17, 2024 | 10:42 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on PDS Biotechnology, maintaining a price target of $21. Analyst Joseph Pantginis continues to support the stock's potential.
The reiteration of a Buy rating and maintenance of a $21 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100